会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明公开
    • MEDICINAL AGENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS OR PREVENTING PROGRESSION OF PHASE OF AMYOTROPHIC LATERAL SCLEROSIS
    • 药物肌萎缩侧索硬化症的治疗或预防肌萎缩性侧索硬化的进展
    • EP2754440A1
    • 2014-07-16
    • EP12830484.7
    • 2012-09-05
    • Mitsubishi Tanabe Pharma Corporation
    • YONEOKA, Takatomo
    • A61K31/4152A61P11/16A61P21/02A61P21/04A61P25/00C07D231/26
    • A61K31/4015A61K31/4152C07D231/26
    • It is an object of the present invention to provide a novel pharmaceutical agent or method for treating ALS or suppressing the disease progress thereof, or treating symptoms caused by ALS or suppressing the disease progress thereof, wherein the agent can be administered particularly to patients obtaining high therapeutic effects, among ALS patients who require treatments. According to the present invention, there is provided a pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing the disease progress thereof or treating symptoms caused by amyotrophic lateral sclerosis or suppressing the disease progress thereof, which comprises, as an active ingredient, 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof, wherein the agent is administered by repeating a 14-day administration period and a 14-day drug holiday period, or by establishing an initial 14-day administration period and an initial 14-day drug holiday period and then repeating an administration period for 10 out of 14 days and a 14-day drug holiday period, and wherein a patient administered with the agent complies with specific criteria.
    • 本发明提供一种治疗ALS或抑制它们的疾病的进展,或治疗由ALS引起的症状或抑制它们的病情进展,worin药剂的新型药剂或方法的一个对象可以特别施用于患者获得高 治疗效果,谁需要治疗ALS患者中。 。根据本发明,提供了一种药剂用于治疗肌萎缩侧索硬化症或抑制它们的病情进展或治疗由肌萎缩侧索硬化症引起的症状或抑制疾病进展物,其包含作为活性成分的,3-甲基 1-苯基-2-吡唑啉-5-酮或其生理学上可接受的盐,其中所述试剂是通过重复14天给药期和14天的休药期期间给药,或通过在初始14天的给药期建立 和初始14天休药期,然后重复给药期间为10的14天和14天的休药期,worin与代理给予患者特定的标准的规定。